Lianhuang Pharmaceutical: Holding subsidiary obtains the "Drug Registration Certificate" for Extended-release tablets of Dapagliflozin and Metformin Hydrochloride

Lianhuan Pharmaceutical announced that its holding subsidiary, Changle Pharmaceutical, recently received the Drug Registration Certificate for Dapagliflozin Metformin Sustained-Release Tablets issued by the National Medical Products Administration. This drug is used to improve blood sugar control in adult patients with type 2 diabetes. In the first quarter of 2026, the sales of Dapagliflozin Metformin Sustained-Release Tablets in national hospitals of at least secondary level reached 246.0658 million yuan. Changle Pharmaceutical invested approximately 9.63 million yuan in the research and development of this drug, and the company and its subsidiaries obtained a total of 10 production approvals in 2026. This certification enriches the product line, but is not expected to have a significant impact on the company's performance in the near future. There are uncertainties in drug production and sales, so investors are reminded to pay attention to risks.